ARWR - Arrowhead Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.49
-0.38 (-2.74%)
At close: 4:00PM EDT

13.50 +0.01 (0.07%)
Pre-Market: 7:43AM EDT

Stock chart is not supported by your current browser
Previous Close13.87
Open13.53
Bid13.50 x 1000
Ask13.78 x 1000
Day's Range13.30 - 14.23
52 Week Range3.01 - 22.39
Volume1,992,958
Avg. Volume2,592,895
Market Cap1.187B
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateDec 10, 2018 - Dec 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.30
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

  • CNBC2 days ago

    Johnson & Johnson tops third-quarter earnings, revenue estimates

    Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged.

  • Johnson & Johnson tops third-quarter earnings, revenue estimates
    CNBC2 days ago

    Johnson & Johnson tops third-quarter earnings, revenue estimates

    Pharmaceuticals have been fueling J&J's growth while its consumer and medical device businesses have lagged.

  • Business Wire3 days ago

    Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3

    — Arrowhead to host R&D Day October 16, 2018 to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics

  • This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging
    Motley Fool6 days ago

    This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging

    Find out which earnings report you really need to pay attention to next week.

  • Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September
    Motley Fool7 days ago

    Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September

    Investors are excited about data for its hepatitis B drug.

  • Business Wire7 days ago

    Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018

    Arrowhead Pharmaceuticals Inc. will make two late-breaking poster presentations at The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease being held on November 9-13, 2018, in San Francisco.

  • ACCESSWIRE8 days ago

    Major Biotech Announcements Moving the Market

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...

  • Why Arbutus Biopharma Stock Plunged 24.4% Today
    Market Realist9 days ago

    Why Arbutus Biopharma Stock Plunged 24.4% Today

    Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.

  • JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug
    Market Realist10 days ago

    JNJ’s $3.7 Billion Deal for Hepatitis B Gene Silencing Drug

    On October 4, Johnson & Johnson (JNJ) announced an exclusive worldwide license agreement with Arrowhead Pharmaceuticals (ARWR) to develop and commercialize the latter’s Phase 1/2 drug candidate for the treatment of chronic Hepatitis B viral infection.

  • How Is Arrowhead Pharmaceuticals Stock Positioned?
    Market Realist10 days ago

    How Is Arrowhead Pharmaceuticals Stock Positioned?

    When the market opened in 2018, Arrowhead Pharmaceuticals stock was selling at $3.69. Cantor Fitzgerald has raised its target price for Arrowhead Pharmaceuticals to $24 from $18. In July, Chardan Capital raised its price target to $24.50 from $17.50.

  • Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?
    Motley Fool10 days ago

    Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip?

    A market beatdown following some good news has investors scratching their heads.

  • J&J Inks Deal With Arrowhead for Promising Liver Candidate
    Zacks13 days ago

    J&J Inks Deal With Arrowhead for Promising Liver Candidate

    Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.

  • Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
    Zacks13 days ago

    Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data

    Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / U.S. markets plunged on Thursday as the 10-year U.S. treasury note hit its highest level since 2011, dampening investors' enthusiasm for stocks. The Dow Jones ...

  • The Wall Street Journal14 days ago

    [$$] Honey, I Shrunk the Biotech Deal

    Arrowhead Pharmaceuticals touted a deal with Johnson & Johnson with a price tag more than the double the company’s market value, but the actual figure may be far smaller.

  • Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges
    Investing.com14 days ago

    Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges

    Investing.com - Stocks in focus in pre-market trade Thursday:· Barnes & Noble (NYSE:BKS) stock jumped 21.25% as of 8:20 AM ET (12:20 GMT) after the struggling bookstore chain announced it was exploring a takeover.· Tilray (NASDAQ:TLRY) stock slumped 3.72% after the company announced it was offering $400 million worth of convertible senior notes to be used for working capital, acquisitions and to repay a $9.1 million mortgage on a production facility in British Columbia.· Apple (NASDAQ:AAPL) and Amazon. ...

  • J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
    Reuters14 days ago

    J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

    Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide license for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology. J&J's investment comes a month after Arrowhead released data from an early trial testing ARO-HBV, dubbed "revolutionary" by analysts who also said the company was positioned to develop a functional cure for Hepatitis B.

  • Business Wire14 days ago

    Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen

    - Upon closing, Arrowhead to receive $250 million, consisting of $175 million upfront payment from Janssen and $75 million equity investment from Johnson & Johnson Innovation – JJDC, Inc. Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize ARO-HBV.

  • Business Wire23 days ago

    Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

    Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:

  • Business Wire24 days ago

    Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City. The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU Langone Medical Center) who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia. Arrowhead's management team will provide an overview of the company’s pipeline of RNAi-based therapeutics.

  • Business Wire27 days ago

    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

    Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on September 14, 2018, the Board of Directors approved "inducement" grants to nine new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 104,000 shares of common stock. The strike price of options is set at an exercise price per share of $18.91, the last reported closing price of the Company's common stock on September 14, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of five new employees, anticipated to be within 30 days of the date of the approval.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals

    On Thursday, President Donald Trump instructed aides to carry on with $200 billion tariffs against Chinese goods. The Nasdaq Composite Index dropped 0.05 percent to close at 8,010.04, gained 1.4 percent for the week.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Big news lit a fire under these biotech stocks this week. But can their momentum continue?

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning ...